Cargando…

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1

The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Toi, Masakazu, Boyle, Frances, Im, Young-Hyuck, Reinisch, Mattea, Molthrop, David, Jiang, Zefei, Wei, Ran, Sapunar, Francisco, Grimes, Brenda R, Nabinger, Sarah Cassidy, Johnston, Stephen R D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847542/
https://www.ncbi.nlm.nih.gov/pubmed/36342342
http://dx.doi.org/10.1093/oncolo/oyac234
_version_ 1784871478462775296
author Toi, Masakazu
Boyle, Frances
Im, Young-Hyuck
Reinisch, Mattea
Molthrop, David
Jiang, Zefei
Wei, Ran
Sapunar, Francisco
Grimes, Brenda R
Nabinger, Sarah Cassidy
Johnston, Stephen R D
author_facet Toi, Masakazu
Boyle, Frances
Im, Young-Hyuck
Reinisch, Mattea
Molthrop, David
Jiang, Zefei
Wei, Ran
Sapunar, Francisco
Grimes, Brenda R
Nabinger, Sarah Cassidy
Johnston, Stephen R D
author_sort Toi, Masakazu
collection PubMed
description The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2− early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]).
format Online
Article
Text
id pubmed-9847542
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-98475422023-01-20 Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1 Toi, Masakazu Boyle, Frances Im, Young-Hyuck Reinisch, Mattea Molthrop, David Jiang, Zefei Wei, Ran Sapunar, Francisco Grimes, Brenda R Nabinger, Sarah Cassidy Johnston, Stephen R D Oncologist Brief Communication The monarchE Cohort 1 patient population was enrolled based on high-risk clinicopathological features that can easily be identified as part of routine clinical breast cancer evaluation. Efficacy data from Cohort 1 demonstrate substantial evidence of benefit for adjuvant abemaciclib+ET in patients with HR+, HER2− early breast cancer at high risk of recurrence (ClinicalTrials.gov: NCT03155997 [monarchE]). Oxford University Press 2022-11-07 /pmc/articles/PMC9847542/ /pubmed/36342342 http://dx.doi.org/10.1093/oncolo/oyac234 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Brief Communication
Toi, Masakazu
Boyle, Frances
Im, Young-Hyuck
Reinisch, Mattea
Molthrop, David
Jiang, Zefei
Wei, Ran
Sapunar, Francisco
Grimes, Brenda R
Nabinger, Sarah Cassidy
Johnston, Stephen R D
Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
title Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
title_full Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
title_fullStr Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
title_full_unstemmed Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
title_short Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
title_sort adjuvant abemaciclib combined with endocrine therapy: efficacy results in monarche cohort 1
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847542/
https://www.ncbi.nlm.nih.gov/pubmed/36342342
http://dx.doi.org/10.1093/oncolo/oyac234
work_keys_str_mv AT toimasakazu adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT boylefrances adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT imyounghyuck adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT reinischmattea adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT molthropdavid adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT jiangzefei adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT weiran adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT sapunarfrancisco adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT grimesbrendar adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT nabingersarahcassidy adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1
AT johnstonstephenrd adjuvantabemaciclibcombinedwithendocrinetherapyefficacyresultsinmonarchecohort1